Your browser doesn't support javascript.
loading
Can Targeted Protein Degradation Technology Provide a Potential Breakthrough in the Development of Anti-AD Drugs?
Xiong, Baichen; Song, Zuoaoyun; Wang, Leyan; Zhang, Ao; Zhou, Yu; Zheng, Na; Wei, Yuqing; Chen, Yao; Sun, Haopeng.
Afiliación
  • Xiong B; School of Pharmacy, China Pharmaceutical University, Nanjing 211198, People's Republic of China.
  • Song Z; School of Pharmacy, China Pharmaceutical University, Nanjing 211198, People's Republic of China.
  • Wang L; School of Life Science and Technology, China Pharmaceutical University, Nanjing 211198, People's Republic of China.
  • Zhang A; School of Pharmacy, Nanjing University of Chinese Medicine, Nanjing 210023, People's Republic of China.
  • Zhou Y; School of Pharmacy, China Pharmaceutical University, Nanjing 211198, People's Republic of China.
  • Zheng N; School of Pharmacy, China Pharmaceutical University, Nanjing 211198, People's Republic of China.
  • Wei Y; School of Pharmacy, China Pharmaceutical University, Nanjing 211198, People's Republic of China.
  • Chen Y; School of Pharmacy, Nanjing University of Chinese Medicine, Nanjing 210023, People's Republic of China.
  • Sun H; School of Pharmacy, China Pharmaceutical University, Nanjing 211198, People's Republic of China.
ACS Chem Neurosci ; 15(19): 3434-3436, 2024 Oct 02.
Article en En | MEDLINE | ID: mdl-39354828
ABSTRACT
Recent advancements in Alzheimer's disease (AD) research have led to the approval of lecanemab and donanemab, highlighting the effectiveness of amyloid-beta (Aß) degradation as a treatment for AD. The prospect of small molecule Aß degraders as a potential treatment, which utilizes emerging targeted protein degradation technology, is exciting, given their ability to address some of the limitations of current therapies and their promising future in AD treatment. Despite facing challenges, these degraders are poised to become a future treatment option, harnessing scientific breakthroughs for more targeted and effective AD therapy.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Péptidos beta-Amiloides / Enfermedad de Alzheimer / Proteolisis Límite: Animals / Humans Idioma: En Revista: ACS Chem Neurosci Año: 2024 Tipo del documento: Article Pais de publicación: Estados Unidos

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Péptidos beta-Amiloides / Enfermedad de Alzheimer / Proteolisis Límite: Animals / Humans Idioma: En Revista: ACS Chem Neurosci Año: 2024 Tipo del documento: Article Pais de publicación: Estados Unidos